Navigation Links
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Date:5/22/2008

SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II pivotal study.

The interim results of this Phase I/II study of targeted gene delivery in vivo are very encouraging -- intravenous infusions of Rexin-G demonstrated significant biological activity without toxicity in patients with rapidly progressive chemo-resistant breast cancer. Once the general safety of repeated infusions of Rexin-G was documented, the FDA approved across the board intra-patient dose-escalations in order to gain better tumor control. These escalating doses of Rexin-G were associated with stabilization of disease, using both RECIST and International PET criteria, significant reductions in CA 15.3 levels, a median progression-free survival of 6 months (RECIST) and a median over-all survival of greater than 7 months with all patients surviving at the 8-month follow-up period. No dose-limiting toxicity was observed, even at the higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated.

According to Dr. Erlinda M. Gordon, Medical Director of Epeius, "The importance of these dose-escalation studies -- which clearly establish safety before escalating to more potent tumoricidal levels -- is a primary concern in the development of a new genetic medicine like Rexin-G." Taken together with the results of previous studie
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
2. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
5. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
9. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
10. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
11. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... Diagnostics today announced a collaboration with Merck, known as MSD ... Canada , to develop Daktari,s rapid hepatitis C ... million over the next 3.5 years, will support an accelerated ... Daktari,s HCV test. The Daktari technology forms ... levels of virus directly in a single drop of blood ...
(Date:8/31/2015)... Aug. 31, 2015  On August 5, 2015, the ... Oregon denied motions to dismiss securities class ... ) and certain of its directors. The class actions ... and dump" scheme to artificially inflate Galena,s stock price, ... stock price was inflated, sold massive amounts of their ...
Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2
... May 15, 2012  Boston Scientific Corporation (NYSE: ... trial, which evaluated the acute safety of the Lotus™ ... disease.  The Lotus Aortic Valve System is the first ... that is designed to minimize aortic regurgitation (leaking) and ...
... year,s Annual Scientific Meeting of the American Pain ... will present results from clinical studies utilizing a ... is designed to be crush-resistant and to protect ... to prescription opioid drugs is considered an efficient ...
Cached Medicine Technology:Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 2Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 3Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 4Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 5INTAC™ Technology Combats Misuse of Extended Release Drugs 2
(Date:8/31/2015)... ... 31, 2015 , ... Diablo Publications (DP), a ... has officially launched a new website and company identity ( diablopublications.com) . According ... closely aligned with the company’s strategic vision for growth and expansion over the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... AdvantaClean franchise business with a ribbon-cutting ceremony on Aug. 26, generously hosted by ... and booking inspection appointments via AdvantaClean’s National Call Center and website since Aug. ...
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... ... and provider of the CME-certified annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy ... to be held Nov. 4 – 6 in New York City. The annual ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... peers may be at a greater risk for injury, potentially because they are ... University of Pittsburgh Graduate School of Public Health analysis discovered. , The ...
(Date:8/31/2015)... ... 2015 , ... On Saturday, May 30th, 2015, Best Drug Rehabilitation sponsored a ... Mendon, IL. The purpose behind this concert was to raise money for music education ... Drug Rehabilitation’s sponsorship of “Music with a Mission” helped with a portion of the ...
Breaking Medicine News(10 mins):Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3
... Improved Benefits for Prevention, Mental,Health and Low-Income ... Pa., June 12 SUMMARY: Today a,minority ... to protect and,improve Medicare for the 44 ... Improvements for Patients and Providers Act, which ...
... by Senate Vote to Block Medicare Improvement Bill, ... Prevention, Mental,Health and Low-Income Programs, Boosted Quality through ... was issued,today by AARP Maryland:, SUMMARY: Today ... to protect and improve Medicare for the 44 ...
... on food safety , , THURSDAY, June 12 (HealthDay News) ... outbreak of salmonella-contaminated tomatoes has risen to 228 in ... Thursday. , Also Thursday, Congressional investigators said the U.S. ... own stated goals of protecting the nation,s food supply. ...
... physicians to more accurately diagnose and treat heart ... to Syntermed, an Atlanta-based nuclear medicine imaging and ... analysis (MHPA), a technology developed by Emory medical ... , MHPA is designed to quickly and reliably ...
... Facilities Provide a Unique Market ... ... today,that it has been awarded a coveted Federal Supply Contract (Contract ... the company to market and sell the LifeBed(TM) Patient Vigilance,System to ...
... head trauma deaths since law revoked in 2003 , , ... years after Pennsylvania repealed its universal motorcycle helmet law, ... injury deaths and a 42 percent increase in head ... The state,s universal helmet law was repealed in 2003. ...
Cached Medicine News:Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 4Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 5Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:Hoana Medical, Inc. Awarded a Federal Supply Contract Through the U.S. Department of Veteran Affairs 2Health News:Pennsylvania Injuries Rise After Repeal of Helmet Law 2
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: